2021 3

IFRS2021 3 2021 3

1. 1.2. 2.3. 3.4. 4.5. 5.6.7.8.9.

1011

iii iii iv

v vi

補-1

1

(

20/3 21/3 21/3 22/3

13,008 12,495 -513 -3.9% 12,565 13,230 5.9%2,767 2,461 -307 -11.1%

( ) 21.3% 19.7%10,241 10,035 -206 -2.0%4,993 5,043 50 1.0% 5,410 7.3%

( ) 38.4% 40.4% 40.9% 1,724 1,807 83 4.8% 1,798 1,822 24 1.3% 1,470 1,414 -56 -3.8%

2,242 2,245 3 0.1% 2,335 2,420 7.8%( ) 17.2% 18.0% 18.6% 18.3%

212 238 26 12.3%-17 5 21 -122 76 -45 -37.2%

39 0 -39 -99.4% 4 36 32 738.0%

459 1,230 770 167.8% 138 1,017 880 637.5% 18 93 75 408.0% 89 23 -66 -73.9% 112 60 -52 -46.3%

2,440 1,361 -1,079 -44.2% 2,105 2,650 94.8%( ) 18.8% 10.9% 16.8% 20.0%

44 116 72 166.0%30 23 -7 -22.3%

2,454 1,453 -1,000 -40.8% 2,095 2,630 81.0%( ) 18.9% 11.6% 16.7% 19.9%

499 247 -252 -50.5%1,954 1,206 -748 -38.3% 1,695 2,090 73.3%

( ) 15.0% 9.7% 13.5% 15.8%1,567 1,815 248 15.8%

補-2

2 (

20/3 21/3 21/3 22/3

13,008 12,495 -513 -3.9% 12,565 13,230 5.9%2,767 2,461 -307 -11.1%

( ) 21.3% 19.7%10,241 10,035 -206 -2.0%4,993 5,043 50 1.0% 5,410 7.3%

( ) 38.4% 40.4% 40.9% 1,724 1,807 83 4.8% 1,798 1,822 24 1.3% 1,470 1,414 -56 -3.8%

2,242 2,245 3 0.1% 2,335 2,420 7.8%( ) 17.2% 18.0% 18.6% 18.3%

212 238 26 12.3%-17 5 21 -

2,778 2,514 -264 -9.5% 2,510 2,700 7.4%( ) 21.4% 20.1% 20.0% 20.4%

44 116 72 166.0%30 23 -7 -22.3%

2,791 2,606 -185 -6.6%( ) 21.5% 20.9%

559 507 -52 -9.3%2,232 2,099 -133 -5.9% 2,005 2,130 1.5%

( ) 17.2% 16.8% 16.0% 16.1%

320/3 21/3 20/3 21/3 21/3 22/3

USD 109 106 109 111 109 110 EUR 121 124 120 130 120 130

1 46 732 +0.8ppt

補-3

4

13,008 - 13,008 12,495 - 12,495 2,767 - 2,767 2,461 - 2,461

10,241 - 10,241 10,035 - 10,035 4,993 - 4,993 5,043 - 5,043 2,242 - 2,242 2,245 - 2,245

212 - 212 238 - 238 -17 - -17 5 - 5

* 122 -122 - 76 -76 - * 459 -459 - 1,230 -1,230 -

2,440 338 2,778 1,361 1,153 2,514 44 - 44 116 - 116 30 - 30 23 - 23

2,454 338 2,791 1,453 1,153 2,606 499 60 559 247 260 507

1,954 278 2,232 1,206 893 2,099

20/3 21/3

*

補-4

5 (20/3 21/3 21/3 22/3

13,008 12,495 -513 -3.9% 12,565 13,230 5.9%3,454 2,791 -663 -19.2% 2,817 2,498 -10.5%

( ) 26.6% 22.3% 22.4% 18.9%4,435 4,732 297 6.7% 4,864 5,446 15.1%

( ) 34.1% 37.9% 38.7% 41.2%2,961 2,932 -29 -1.0% 2,875 3,319 13.2%

( ) 22.8% 23.5% 22.9% 25.1%604 593 -11 -1.8% 672 638 7.7%

( ) 4.6% 4.7% 5.4% 4.8%1,348 1,111 -237 -17.6% 1,171 1,227 10.4%

( ) 10.4% 8.9% 9.3% 9.3%207 336 129 62.3% 165 101 -70.1%

( ) 1.6% 2.7% 1.3% 0.8%123

620/3 21/3 21/3 22/3

( 1,861,787 1,861,787 4,276 8,758

1,857,511 1,853,029 104.15 64.93 91.25 112.79 118.95 113.03 107.94 114.95

40 42 42 50 ROE % 15.3% 9.0%DOE % 5.9% 5.8%

7

(20/3 21/3 21/3 22/3

418 337 -81 -19.3% 290 360 6.8%

375 400 25 6.6% 410 430 7.5%

289 327 38 13.1% 300 390 19.4%

補-5

8

1) (20/3 21/3 21/3 22/3

XTANDI/ 4,000 4,584 584 14.6% 4,646 5,572 21.5%2,035 2,386 351 17.3% 2,495 2,880 20.7%1,965 2,198 233 11.9% 2,151 2,692 22.5%

358 402 44 12.4% 389 454 12.8%EM 1,354 1,493 138 10.2% 1,429 1,830 22.6%

32 49 17 52.8% 69 70 43.6%INT 221 255 34 15.2% 264 338 32.7%

143 238 96 67.2% 231 367 53.8%28 38 10 35.4% 32 44 16.0%

105 155 50 47.0% 138 200 29.3%EM 9 44 35 370.5% 55 98 123.2%

- 0 0 - 16 -INT - 2 2 - 9 488.4%

PADCEV 18 128 110 607.3% 130 201 57.1%18 128 110 607.3% 130 191 49.3%2 11 9 371.2% 86 661.0%2 11 9 371.2% 41 262.8%

/ / 1,616 1,636 20 1.2% 1,679 1,752 7.1%343 351 7 2.1% 342 358 2.2%892 880 -13 -1.4% 908 942 7.0%

EM 282 299 17 6.0% 305 356 19.1%14 22 8 59.3% 31 25 15.0%

INT 84 85 1 0.8% 93 71 -15.9%447 316 -131 -29.3% 300 161 -49.2%202 185 -17 -8.4% 171 55 -70.4%54 22 -33 -60.1% 22 12 -43.3%

EM 131 62 -68 -52.4% 52 49 -21.5%18 10 -8 -44.6% 12 8 -23.4%

INT 42 37 -4 -10.6% 43 37 -1.1%1,929 1,827 -103 -5.3% 1,820 1,926 5.5%

443 407 -36 -8.1% 405 385 -5.5%132 118 -14 -10.5% 121 111 -6.1%

EM 715 642 -73 -10.3% 626 698 8.8%322 342 20 6.2% 351 371 8.4%

INT 317 317 0 0.1% 316 362 14.1%/ 427 369 -57 -13.5% 391 343 -7.1%

/ 352 256 -96 -27.3% 231 147 -42.5%142 95 -48 -33.4% 123 - -

12 EM34 INT

補-6

2)

(20/3 21/3 21/3 22/3

358 402 44 12.4% 389 454 12.8%28 38 10 35.4% 32 44 16.0%2 11 9 371.2% 41 262.8%

343 351 7 2.1% 342 358 2.2%202 185 -17 -8.4% 171 55 -70.4%443 407 -36 -8.1% 405 385 -5.5%41 30 -11 -27.1% 26 21 -28.9%76 44 -31 -41.6% 36 18 -58.3%

[ ] 239 279 40 16.8% 303 303 8.6%89 113 24 26.8%31 51 20 62.4%56 64 8 14.7% 66 69 7.9%45 45 1 1.4%

236 248 12 4.9%3 17 14 463.9% 31 89.5%

492 189 -303 -61.6% 209141 - -141 - - - -77 25 -52 -67.7% 50 45 79.8%

112 79 -33 -29.4% 74 77 -3.2%51 51 -0 -0.5% 55 50 -1.7%93 100 8 8.6% 94

[ ] 177 - -177 - - - -60 38 -22 -36.9% 32 29 -23.2%

127 106 -21 -16.5% 10290 78 -12 -13.4% 72 67 -15.0%

3,421 2,766 -656 -19.2% 2,756 2,476 -10.5%

補-7

M20/3 21/3 21/3 22/3

4,078 4,462 383 9.4% 4,446 4,951 11.0%XTANDI 1,871 2,250 379 20.2% 2,280 2,618 16.4%

97 146 49 50.8% 126 182 24.6%PADCEV 17 121 104 625.2% 119 174 43.9%

821 829 9 1.1% 830 856 3.2%50 20 -30 -59.1% 20 11 -45.3%

122 112 -10 -8.2% 111 101 -9.5%106 83 -24 -22.4% 62 17 -78.9%116 114 -3 -2.3% 106 115 1.0%155 160 5 3.0% 155 176 10.6%694 623 -71 -10.3% 626 700 12.5%30 5 -25 -83.8%

M€20/3 21/3 21/3 22/3

2,451 2,370 -81 -3.3% 2,403 2,553 7.7%XTANDI 1,121 1,207 86 7.6% 1,195 1,408 16.7%

8 36 28 359.5% 46 75 112.3%233 241 8 3.5% 255 274 13.3%108 50 -58 -53.5% 43 38 -25.3%592 519 -73 -12.3% 524 537 3.5%71 65 -6 -9.0% 63 63 -3.7%56 45 -11 -20.1% 40 22 -51.2%98 64 -33 -34.3% 81 - -

補-8

(20/3 21/3 21/3 22/3

604 593 -11 -1.8% 672 638 7.7%XTANDI 32 49 17 52.8% 69 70 43.6%

- 0 0 - 16 -14 22 8 59.3% 31 25 15.0%18 10 -8 -44.6% 12 8 -23.4%

322 342 20 6.2% 351 371 8.4%131 108 -22 -17.1% 114 80 -26.4%38 25 -13 -34.3% 37 34 37.7%3 3 0 2.9% 4 - -

25 26 1 4.5% 39 30 12.9%

(20/3 21/3 21/3 22/3

1,348 1,111 -237 -17.6% 1,171 1,227 10.4%XTANDI 221 255 34 15.2% 264 338 32.7%

- 2 2 - 9 488.4%84 85 1 0.8% 93 71 -15.9%42 37 -4 -10.6% 43 37 -1.1%

317 317 0 0.1% 316 362 14.1%169 151 -18 -10.7% 176 161 6.6%55 44 -11 -20.2% 42 47 7.3%

補-9

9

23,152 22,736 -415 14,477 14,010 -466 2,686 2,646 -40 2,783 2,840 58 7,248 6,514 -733

340 339 -1 47 71 24

529 542 13 743 959 216 102 99 -3

8,675 8,726 51 1,510 1,641 131 3,470 3,432 -39

236 140 -96 95 56 -39

180 197 16 3,184 3,261 77

23,152 22,736 -415 12,892 13,861 969 12,892 13,861 969 1,030 1,030 - 1,775 1,778 3

-72 -154 -82 9,059 9,533 474 1,100 1,674 574

10,260 8,875 -1,385 2,273 2,951 678

31 4 -27 247 182 -65 381 390 9 61 58 -3

1,293 1,990 697 260 328 68

7,987 5,924 -2,063 1,720 1,248 -472

40 84 44 142 222 79

3,457 1,482 -1,975 2,628 2,889 261

2020 Audentes

20/3 21/3

20/3 21/3

補-10

1020/3 21/3

15,883 15,455

1120/3 21/3

35.6% 38.3%2.8% 4.3%3.2% 3.1%

49.8% 45.6%8.6% 8.6%

* 0.1% 0.1%* BIP ESOP

補-11

121/3

4-6 7-9 10-12 1-3(%) (%) (%) (%)

3,070 -8.1% 3,085 -2.5% 3,254 -3.7% 3,086 -1.2%597 -15.4% 599 -12.4% 682 -17.6% 583 5.9%

( ) 19.4% 19.4% 21.0% 18.9%2,473 -6.2% 2,486 0.3% 2,572 0.8% 2,503 -2.7%1,208 2.8% 1,214 11.8% 1,209 -5.2% 1,413 -3.1%

( ) 39.3% 39.3% 37.2% 45.8% 420 1.8% 426 5.6% 432 -3.7% 529 15.1% 457 4.8% 446 4.2% 436 0.8% 483 -3.7% 331 1.5% 342 34.2% 341 -13.4% 400 -19.3%

573 7.1% 544 5.7% 571 4.3% 557 -13.7%( ) 18.7% 17.6% 17.6% 18.0%

59 -18.4% 57 41.6% 57 35.6% 65 13.0%-0 - -2 - 0 - 7 43.5%22 -50.4% 32 19.0% 39 -50.5% 27 14.2%

9 - 31 - 0 - - -48 -60.6% 441 - 47 - 738 94.9%

33 - 313 - 21 - 651 374.6% - - 9 - 19 - 64 252.2% - - 64 - - - - - 2 -98.5% 42 783.4% 2 275.4% 19 -

608 -21.1% 261 -69.4% 726 -3.8% -234 -469.8%( ) 19.8% 8.4% 22.3% -7.6%

4 -50.5% 31 437.8% 31 22.6% 51 858.7%10 -27.8% 3 -56.7% 5 46.5% 6 -16.0%

602 -21.3% 289 -66.1% 751 -3.2% -189 -406.6%( ) 19.6% 9.4% 23.1% -6.1%

98 -45.4% 64 -57.3% 151 -6.5% -66 -948.3%504 -13.9% 224 -68.0% 601 -2.3% -123 -328.7%

( ) 16.4% 7.3% 18.5% -4.0%554 104.9% 227 -52.3% 778 -18.8% 256 287.1%

補-12

2

21/34-6 7-9 10-12 1-3

(%) (%) (%) (%)3,070 -8.1% 3,085 -2.5% 3,254 -3.7% 3,086 -1.2%

597 -15.4% 599 -12.4% 682 -17.6% 583 5.9%( ) 19.4% 19.4% 21.0% 18.9%

2,473 -6.2% 2,486 0.3% 2,572 0.8% 2,503 -2.7%1,208 2.8% 1,214 11.8% 1,209 -5.2% 1,413 -3.1%

( ) 39.3% 39.3% 37.2% 45.8% 420 1.8% 426 5.6% 432 -3.7% 529 15.1% 457 4.8% 446 4.2% 436 0.8% 483 -3.7% 331 1.5% 342 34.2% 341 -13.4% 400 -19.3%

573 7.1% 544 5.7% 571 4.3% 557 -13.7%( ) 18.7% 17.6% 17.6% 18.0%

59 -18.4% 57 41.6% 57 35.6% 65 13.0%-0 - -2 - 0 - 7 43.5%

634 -25.2% 669 -19.6% 735 8.0% 476 13.9%( ) 20.6% 21.7% 22.6% 15.4%

4 -50.5% 31 437.8% 31 22.6% 51 858.7%10 -27.8% 3 -56.7% 5 46.5% 6 -16.0%

628 -25.4% 697 -16.2% 760 8.4% 521 25.2%( ) 20.5% 22.6% 23.4% 16.9%

108 -36.7% 155 8.2% 155 9.4% 89 -13.9%520 -22.5% 542 -21.3% 605 8.1% 433 38.1%

( ) 16.9% 17.6% 18.6% 14.0%

補-13

321/3

4-6 7-9 10-12 1-3(%) (%) (%) (%)

3,070 -8.1% 3,085 -2.5% 3,254 -3.7% 3,086 -1.2%778 -21.0% 665 -21.7% 776 -16.5% 573 -17.2%

( ) 25.3% 21.5% 23.8% 18.6%1,172 11.3% 1,196 7.3% 1,191 3.4% 1,174 5.2%

( ) 38.2% 38.8% 36.6% 38.0%640 -15.5% 748 5.4% 791 11.0% 752 -3.7%

( ) 20.9% 24.3% 24.3% 24.4%142 -3.4% 153 4.4% 143 -4.5% 155 -3.4%

( ) 4.6% 5.0% 4.4% 5.0%302 -11.8% 265 -8.9% 309 -21.8% 235 -26.4%

( ) 9.8% 8.6% 9.5% 7.6%36 -36.4% 58 9.3% 46 3.1% 197 265.0%

( ) 1.2% 1.9% 1.4% 6.4%123

421/3

4-6 7-9 10-12 1-3(%) (%) (%) (%)

71 -43.8% 75 -24.2% 93 -1.3% 98 -0.2%

100 24.5% 100 20.8% 101 -9.2% 99 -1.9%

80 -10.9% 80 35.7% 81 33.5% 86 8.1%

補-14

5

1) 21/3

4-6 7-9 10-12 1-3(%) (%) (%) (%)

XTANDI/ 1,120 16.6% 1,135 14.7% 1,172 13.9% 1,157 13.3%627 33.7% 584 12.8% 589 10.7% 586 13.5%493 0.3% 551 16.7% 583 17.3% 571 13.1%101 9.1% 98 4.0% 111 22.1% 92 15.1%

EM 315 -6.4% 374 15.1% 400 20.9% 405 11.5%7 31.4% 16 219.0% 9 33.3% 17 14.4%

INT 69 22.7% 64 32.3% 63 -8.0% 58 22.3%56 128.3% 53 64.4% 67 65.0% 62 37.8%10 70.3% 8 25.6% 11 17.6% 9 38.4%36 92.3% 37 41.8% 43 43.0% 39 27.8%

EM 10 - 8 - 13 739.0% 12 60.4%PADCEV 30 - 31 - 33 - 35 91.2%

30 - 31 - 33 - 35 91.2%2 - 2 - 4 119.6% 4 513.4%2 - 2 - 4 119.6% 4 513.4%

404 1.2% 395 1.8% 423 0.2% 413 1.8%84 -10.5% 82 -2.8% 100 4.0% 84 22.8%

229 7.7% 211 -0.3% 219 -4.9% 221 -7.2%EM 66 -2.3% 77 12.4% 76 5.4% 79 8.2%

4 12.3% 5 79.8% 6 124.6% 6 44.9%INT 20 -2.5% 20 -3.9% 23 4.1% 22 5.2%

77 -43.0% 84 -26.5% 85 -23.6% 70 -18.7%49 -13.8% 44 -8.4% 52 -6.9% 39 -3.0%4 85.7% 12 -51.4% 3 -82.6% 3 -73.3%

EM 13 -79.2% 16 -37.4% 17 -20.9% 16 -27.3%2 -52.9% 3 -44.1% 3 -42.9% 3 -37.5%

INT 9 -14.3% 9 -16.5% 10 -8.6% 9 -1.6%453 -10.2% 443 -3.2% 487 -2.6% 443 -5.1%111 -9.1% 100 -6.7% 111 -8.0% 86 -8.5%36 10.1% 30 -21.0% 28 -27.3% 24 6.7%

EM 138 -21.9% 166 -0.5% 172 -0.2% 166 -16.8%78 1.3% 84 7.9% 86 11.6% 94 4.4%

INT 90 -6.0% 63 -7.0% 91 -1.4% 73 19.7%/ 106 -3.1% 96 -14.7% 87 -21.1% 80 -15.1%

/ 71 -21.6% 69 -21.4% 61 -35.6% 55 -30.4%31 -16.0% 31 -5.4% 32 -16.0% 1 -96.0%

12 EM34 INT

/ /

補-15

2)

21/34-6 7-9 10-12 1-3

(%) (%) (%) (%)101 9.1% 98 4.0% 111 22.1% 92 15.1%10 70.3% 8 25.6% 11 17.6% 9 38.4%2 - 2 - 4 119.6% 4 513.4%

84 -10.5% 82 -2.8% 100 4.0% 84 22.8%49 -13.8% 44 -8.4% 52 -6.9% 39 -3.0%

111 -9.1% 100 -6.7% 111 -8.0% 86 -8.5%8 -30.5% 7 -28.0% 8 -24.6% 6 -24.0%

15 -24.5% 14 -29.1% 11 -49.3% 4 -70.3%

71 18.3% 67 18.0% 78 15.8% 63 14.9%28 34.9% 27 30.0% 32 23.1% 26 20.1%12 52.5% 13 73.1% 15 66.7% 12 57.2%16 12.3% 15 14.6% 18 15.3% 15 16.5%12 12.0% 10 -12.0% 12 -6.4% 11 15.9%69 96.1% 58 -3.0% 63 -9.2% 58 -19.7%2 - 4 365.9% 5 392.2% 5 393.5%

116 -11.9% 27 -79.5% 27 -78.7% 19 -81.1%6 -72.6% 5 -72.7% 9 -60.9% 5 -64.4%0 -99.9% 28 49.0% 51 -17.9% 0 -135.5%

16 23.2% 12 -3.6% 11 -20.2% 11 -0.3%25 4.4% 24 6.9% 28 10.3% 23 13.2%11 -40.4% 10 -37.2% 10 -35.0% 7 -33.5%29 -21.2% 26 -18.1% 29 -12.5% 22 -12.8%21 -17.3% 20 -15.2% 22 -9.3% 16 -11.3%

769 -21.5% 662 -21.6% 765 -16.4% 570 -16.6%

[ ]

補-16

M$

21/34-6 7-9 10-12 1-3

(%) (%) (%) (%)1,089 13.6% 1,126 8.6% 1,139 7.6% 1,108 8.2%

XTANDI 583 36.5% 550 14.2% 564 15.2% 553 16.8%33 96.4% 35 43.8% 41 48.5% 37 31.5%

PADCEV 27 - 29 - 32 - 33 97.7%213 10.0% 199 0.8% 209 -1.0% 208 -4.6%

4 89.6% 11 -50.5% 3 -81.4% 2 -72.5%33 12.4% 28 -19.9% 27 -24.2% 23 10.0%24 -10.5% 22 -21.5% 18 -31.0% 19 -27.1%22 -16.3% 29 0.8% 33 11.7% 28 -6.6%36 -2.3% 40 14.7% 44 0.4% 39 0.8%

111 -40.1% 180 0.6% 165 -3.8% 166 5.2%3 -82.4% 2 -52.9% 2 -70.5% -2 -141.2%

M€

21/34-6 7-9 10-12 1-3

(%) (%) (%) (%)540 -11.9% 604 1.6% 636 7.4% 589 -9.4%

XTANDI 266 -2.4% 302 10.9% 322 17.1% 318 5.2%9 - 7 - 11 719.4% 10 52.4%

56 1.8% 62 8.5% 61 1.9% 62 2.0%11 -78.4% 13 -40.8% 14 -23.8% 13 -31.8%

117 -18.5% 134 -4.1% 138 -3.5% 130 -21.6%15 -11.8% 17 -3.6% 18 -7.1% 16 -13.3%13 -10.0% 11 -25.0% 11 -18.5% 9 -27.7%21 -13.3% 21 -6.4% 22 -16.4% 0 -100.0%

補-17

(

21/34-6 7-9 10-12 1-3

(%) (%) (%) (%)142 -3.4% 153 4.4% 143 -4.5% 155 -3.4%

XTANDI 7 31.4% 16 219.0% 9 33.3% 17 14.4%4 12.3% 5 79.8% 6 124.6% 6 44.9%2 -52.9% 3 -44.1% 3 -42.9% 3 -37.5%

78 1.3% 84 7.9% 86 11.6% 94 4.4%37 12.6% 30 -15.3% 22 -33.6% 19 -34.2%5 -45.6% 7 -6.6% 6 -53.1% 7 -17.0%1 16.8% 1 27.0% 1 27.1% 0 -52.6%6 -2.6% 6 -3.2% 7 13.6% 7 9.7%

(

21/34-6 7-9 10-12 1-3

(%) (%) (%) (%)302 -11.8% 265 -8.9% 309 -21.8% 235 -26.4%

XTANDI 69 22.7% 64 32.3% 63 -8.0% 58 22.3%20 -2.5% 20 -3.9% 23 4.1% 22 5.2%9 -14.3% 9 -16.5% 10 -8.6% 9 -1.6%

90 -6.0% 63 -7.0% 91 -1.4% 73 19.7%42 -1.4% 39 -17.7% 35 -19.6% 34 -1.6%10 -31.2% 10 -15.0% 11 -24.7% 12 -8.0%

補-18

2021 42021 1

1/2

**

2019 7P-

P-

2021 1

P-

P-

P-

P-

P-

PD-1/PD-L1 2021 3

PD-1/PD-L1 2021 2

2021 3

P-

P-

P-

MDV3100®

ASP2215®

Seagen

Pfizer

ASG-22ME

*

-4ADC

FLT3

- ADC

補-19

2/2

**

P-

P-

2020 4

P-

fezolinetantESN364

NK3 P-Ogeda

CIS

Ganymed

FibroGen

*

HIF-PHASP1517/FG-4592

®

IMAB362Claudin 18.2

2021 1MDV3100 2020 11

ASP1517/FG-4592 2020 11ASP2215 FLT3 2021 1

ASG-22ME PD-1/PD-L1 2021 2 PD-1/PD-L12021 3 2021 3

***

補-20

Focus Area 1/2

**

ASP1948/PTZ-329 NRP1 P-Potenza

Therapeutics

ASP1951/PTZ-522 GITR P-Potenza

Therapeutics

ASP9801 IL-7 IL-12 P-

ASP7517 WT1 P-

ASP0739 NY-ESO-1 P-

FX-322

GSK-3HDAC

P- FrequencyTherapeutics

ASP7317 Stargardt P-Astellas Institute

for RegenerativeMedicine

ASP0598 P- Auration Biotech

ASP1128/MA-0217 P-Mitobridge

P-

P-

ASP0367/MA-0211

*

Mitobridge

補-21

Focus Area 2/2

**

resamirigenebilparvovecAT132

MTM1 X P-Audentes

Therapeutics

AT845 GAAGAA

P-Audentes

Therapeutics

ASP3772MAPS MAPS

P- Affinivax

ASP0892LAMP-vax

P- ImmunomicTherapeutics

ASP2390LAMP-vax

P- ImmunomicTherapeutics

***

*

補-22

**

3 2021 3P-P-

FK506®

2020 12

ASP015KJAK P-

bleselumabASKP1240

CD40 P-

ASP1617 P-

isavuconazole P- Basilea

P-

P-

2021 1YM178 3 2021 3

ASP8062 Phase 2

***

YM178

*

ASP8062 GABAB

補-23

Rx+2021 4

2021 1

Fit-eNce

BlueStar

II2021 3

ASP5354

Welldoc

P-

2021 1II

補-24